Amylyx Pharmaceuticals, Inc. (AMLX)
12.57
-0.53
(-4.05%)
USD |
NASDAQ |
Dec 15, 16:00
12.57
0.00 (0.00%)
After-Hours: 18:13
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.380B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 197.1% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 4.158 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0179 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA. |
| URL | http://www.amylyx.com |
| Investor Relations URL | https://investors.amylyx.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 03, 2026 (est.) |
| Last Earnings Release | Nov. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA. |
| URL | http://www.amylyx.com |
| Investor Relations URL | https://investors.amylyx.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 03, 2026 (est.) |
| Last Earnings Release | Nov. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |